Immune globulin sulfonated human - Kaketsuken/Teijin

Drug Profile

Immune globulin sulfonated human - Kaketsuken/Teijin

Alternative Names: Freeze-dried sulfonated human immunoglobulin; GGS-CIDP; GGS-MMN; GGS-MPA; GGS-ON; IVIG - Kaketsuken/Teijin; Sulfonated human immunoglobulin; Venilon

Latest Information Update: 11 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kaketsuken; Teijin
  • Class Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Churg-Strauss syndrome; Infections
  • Phase III Chronic inflammatory demyelinating polyradiculoneuropathy; Microscopic polyangiitis; Motor neuron disease; Optic neuritis
  • Clinical Phase Unknown Idiopathic pulmonary fibrosis
  • Discontinued Multiple sclerosis

Most Recent Events

  • 31 Mar 2016 Freeze-dried sulfonated human immunoglobulin is still in phase III trials for Optic neuritis, Chronic inflammatory demyelinating polyradiculoneuropathy and Microscopic polyangiitis in Japan (IV) (Teijin Pharma pipeline, March 2016)
  • 30 Dec 2013 Phase-III clinical trials in Chronic inflammatory demyelinating polyradiculoneuropathy in Japan (IV) (JapicCTI142471)
  • 01 Dec 2013 Phase-III clinical trials in Microscopic polyangiitis in Japan (IV) (JapicCTI132394)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top